We set out to change the world and make mRNA medicines a reality for humanity.
We’re making biotech history
Messenger RNA is not new technology, but we are discovering new ways to use it to treat and prevent illnesses and diseases. Since our founding in 2010, we have worked to build the industry's leading mRNA technology platform.
Our big moments
Moderna’s name combines the words "modified" and "RNA", which happens to contain the word "modern.”
Moderna begins research into the production of mRNA medicines. Stéphane Bancel joins as founding CEO.
New headquarters and labs open in Cambridge, Massachusetts.
First human dose of flu vaccine
Moderna initiates first-in-human dose of an mRNA vaccine (mRNA-1440), an H10N8 flu vaccine candidate.
New lease signed
Lease signed to build 200,000 sq ft GMP mRNA clinical manufacturing facility in Norwood, MA
First human dose of multivalent vaccine
Moderna initiates first-in-human dosing for mRNA-1653, a combination vaccine with the potential to protect against more than one disease – human metapneumovirus (hMPV virus) and parainfluenza virus.
New facility opens
Moderna opens its state-of-the-art clinical development site in Norwood, MA.
First antibody encoded by mRNA
Moderna announces dosing of the first antibody encoded by mRNA in a clinical trial.
The U.S. Centers for Disease Control and Prevention votes to recommend the use of the Moderna COVID-19 vaccine in people 18 years of age and older in the U.S.
Moderna receives full approval for COVID-19 vaccine by U.S. FDA
The U.S. Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for SPIKEVAX (COVID-19 Vaccine, mRNA) to prevent COVID-19 in individuals 18 years of age and older in the U.S.